Tyrosine kinase inhibitors therapy for hepatocellular carcinoma in patients waiting for liver transplant: is it safe?

被引：0
|
作者：
Conte, G. [1 ]
Mocchegiani, F. [2 ]
Cacciaguerra, A. Benedetti [2 ]
Rossi, R. [3 ]
Vecchi, A. [1 ]
Gaudenzi, F. [2 ]
Roccheggiani, M. [2 ]
Borrelli, G. [2 ]
Quercetti, D. [2 ]
Dalla Bona, E. [1 ]
Nicolini, D. [1 ]
Vivarelli, M. [2 ]
机构：
[1] Osped Riuniti Ancona, Clin Chirurg Epatobiliare Pancreat & Trapianti, Ancona, Italy
[2] Univ Politecn Marche, Ancona, Italy
[3] Ospedali Riuniti Ancona, Clin Chirurg Epatobiliare Pancreat Trapianti, Ancona, Italy
来源：
TRANSPLANTATION | 2023年 / 107卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
eP-460
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [1] Role of hepatocellular carcinoma therapy for patients in the waiting list for liver transplant
    Pascual, S.
    Irurzun, J.
    Miralles, C.
    Bernabe, J. M.
    Rodriguez, M.
    Bellot, P.
    Melgar, P.
    Alcazar, C.
    Lluis, F.
    Palazon, J. M.
    Rodriguz-Laiz, G.
    TRANSPLANTATION, 2021, 105 (08) : 130 - 130
  • [2] Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
    da Fonseca, Leonardo G.
    Reig, Maria
    Bruix, Jordi
    CLINICS IN LIVER DISEASE, 2020, 24 (04) : 719 - 737
  • [3] List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma
    Salvalaggio, P. R.
    Felga, G.
    Axelrod, D. A.
    Della Guardia, B.
    Almeida, M. D.
    Rezende, M. B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (03) : 668 - 677
  • [4] Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
    Park, Hyunjung
    Park, Hyerin
    Baek, Jiyeon
    Moon, Hyuk
    Ro, Simon Weonsang
    BIOLOGY-BASEL, 2022, 11 (04):
  • [5] Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma
    Guo, Yuan
    Li, Ru-Chun
    Xia, Wei-Li
    Yang, Xiong
    Zhu, Wen-Bo
    Li, Fang-Ting
    Hu, Hong-Tao
    Li, Hai-Liang
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (07)
  • [6] Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma
    de Rosamel, Laure
    Blanc, Jean-Frederic
    EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (02) : 175 - 190
  • [7] Combination therapy with Nivolumab/Bevacizumab is safe and effective in patients with recurrent hepatocellular carcinoma after liver transplant
    Di Marco, Lorenza
    Pivetti, Alessandra
    De Maria, Nicola
    Foschi, Francesco Giuseppe
    Romagnoli, Dante
    Casari, Federico
    Caporali, Cristian
    Magistri, Paolo
    Catellani, Barbara
    Di Benedetto, Fabrizio
    Villa, Erica
    CLINICAL CANCER RESEARCH, 2022, 28 (17)
  • [8] IS ISONIAZID SAFE IN LIVER TRANSPLANT PATIENTS ON THE WAITING LIST?
    Stucchi, Raquel S. B.
    Boin, Ilka F. S. F.
    Angerami, Rocrigo N.
    Zanaga, Leticia
    Udo, Elisabete Y.
    Ataide, Elaine C.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 280 - 280
  • [9] Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
    Zhang, Wenwen
    Hu, Bingyang
    Han, Jun
    Wang, Zhanbo
    Ma, Guangyu
    Ye, Huiyi
    Yuan, Jing
    Cao, Junning
    Zhang, Ze
    Shi, Jihang
    Chen, Mingyi
    Wang, Xun
    Xu, Yinzhe
    Cheng, Yanshuang
    Tian, Lantian
    Wang, Hongguang
    Lu, Shichun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] CLINICAL OUTCOME OF TYROSINE KINASE INHIBITORS IN THE GERIATRIC PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Kaneko, Shun
    Wang, Wan
    Kirino, Sakura
    Tamaki, Nobuharu
    Yasui, Yutaka
    Nakanishi, Hiroyuki
    Itakura, Jun
    Izumi, Namiki
    HEPATOLOGY, 2019, 70 : 549A - 550A
12345